Approved indications and other possible utilizations of anti-TNFa biologic drugs

Abstract

The article describes the EMEA approved indications of TNFa antagonists (adalimumab, etanercept and infliximab) in the various clinical conditions and their increasing use in diseases other than those already approved. The Authors discuss their use during pregnancy, the efficacy of a second TNFa antagonist after failure or side effects development with a previous biologic agent and the different efficacy of the various agents depending on the different clinical conditions.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Info
Issue
Section
Articles
Statistics
  • Abstract views: 675

  • PDF: 534
How to Cite
Grassi, W., & Montecucco, C. (1). Approved indications and other possible utilizations of anti-TNFa biologic drugs. Reumatismo, 57(4s), 30-33. https://doi.org/10.4081/reumatismo.2005.4s.30

Most read articles by the same author(s)

1 2 3 4 > >>